Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTHNASDAQ:CLVRNASDAQ:KPRXNASDAQ:LIPO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.17+1.5%$0.38$0.12▼$7.67$1.44M0.131.60 million shs13,192 shsCLVRClever Leaves$0.00$0.00$0.00▼$5.89N/A2882.232,558 shs1 shsKPRXKiora Pharmaceuticals$2.77-1.6%$3.40$2.72▼$5.76$8.30M-0.4632,286 shs8,360 shsLIPOLipella Pharmaceuticals$2.54-1.6%$2.87$2.02▼$12.00$3.07M0.13700,853 shs4,119 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path+3.15%+6.37%-4.38%-85.20%-95.98%CLVRClever Leaves0.00%+100.00%-91.30%0.00%-100.00%KPRXKiora Pharmaceuticals-4.10%-6.02%-8.47%-21.51%-46.90%LIPOLipella Pharmaceuticals+0.39%-0.77%-8.19%-18.87%-53.93%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path1.9174 of 5 stars3.50.00.00.01.70.01.3CLVRClever LeavesN/AN/AN/AN/AN/AN/AN/AN/AKPRXKiora Pharmaceuticals2.9899 of 5 stars3.83.00.00.00.61.71.9LIPOLipella Pharmaceuticals3.3686 of 5 stars3.54.00.00.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 3.00Buy$20.0011,480.78% UpsideCLVRClever Leaves 0.00N/AN/AN/AKPRXKiora Pharmaceuticals 3.50Strong Buy$10.00261.66% UpsideLIPOLipella Pharmaceuticals 3.00Buy$16.00529.92% UpsideCurrent Analyst Ratings BreakdownLatest LIPO, CLVR, BPTH, and KPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACLVRClever Leaves$17.42M0.00N/AN/A$14.02 per share0.00KPRXKiora Pharmaceuticals$16M0.52N/AN/A$7.14 per share0.39LIPOLipella Pharmaceuticals$483.53K6.35N/AN/A$4.33 per share0.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%5/13/2025 (Estimated)CLVRClever Leaves-$17.90M-$11.31N/A∞N/AN/AN/AN/A4/3/2025 (Estimated)KPRXKiora Pharmaceuticals-$12.51M$1.042.66N/AN/AN/A21.32%16.39%5/9/2025 (Estimated)LIPOLipella Pharmaceuticals-$4.62M-$4.72N/A∞N/A-882.82%-192.33%-154.24%5/8/2025 (Estimated)Latest LIPO, CLVR, BPTH, and KPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024LIPOLipella Pharmaceuticals-$2.43-$1.19+$1.24-$1.19N/A$0.17 million3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86CLVRClever LeavesN/AN/AN/AKPRXKiora PharmaceuticalsN/A8.978.97LIPOLipella PharmaceuticalsN/A2.972.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%CLVRClever Leaves6.92%KPRXKiora Pharmaceuticals76.97%LIPOLipella Pharmaceuticals74.31%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%CLVRClever Leaves8.20%KPRXKiora Pharmaceuticals0.94%LIPOLipella Pharmaceuticals32.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path108.31 million5.73 millionOptionableCLVRClever Leaves5601.76 million1.61 millionNo DataKPRXKiora Pharmaceuticals103.00 million2.97 millionNot OptionableLIPOLipella Pharmaceuticals41.21 million821,000Not OptionableLIPO, CLVR, BPTH, and KPRX HeadlinesRecent News About These CompaniesLipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse PodcastMarch 31 at 1:04 PM | prismmediawire.comLipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse PodcastMarch 31 at 11:00 AM | globenewswire.comLipella Pharmaceuticals files to sell 5.62M shares of common stock for holdersMarch 29, 2025 | markets.businessinsider.comSpartan Capital Securities, LLC Announces Key February TransactionsMarch 7, 2025 | globenewswire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private PlacementMarch 4, 2025 | finance.yahoo.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private PlacementMarch 4, 2025 | globenewswire.comBiotech Rips On Topline AnalysisFebruary 11, 2025 | msn.comLipella Pharmaceuticals reports ‘positive’ results from Phase 2a LP-310 trialFebruary 11, 2025 | markets.businessinsider.comLipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen PlanusFebruary 11, 2025 | prismmediawire.comLipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen PlanusFebruary 11, 2025 | globenewswire.comThese 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last WeekFebruary 10, 2025 | msn.comFDA approves Lipella's oral treatment access programFebruary 6, 2025 | msn.comFDA Approves Expanded Access Program For Lipella Pharma's LP-310 In Oral Lichen Planus; Stock UpFebruary 6, 2025 | markets.businessinsider.comLipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen PlanusFebruary 6, 2025 | globenewswire.comLipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen PlanusFebruary 6, 2025 | prismmediawire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private PlacementJanuary 10, 2025 | markets.businessinsider.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc. ...January 10, 2025 | gurufocus.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private PlacementJanuary 10, 2025 | investing.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private PlacementJanuary 10, 2025 | globenewswire.comSpartan Capital Securities, LLC Caps Off a Remarkable Year with Key December TransactionsDecember 31, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIPO, CLVR, BPTH, and KPRX Company DescriptionsBio-Path NASDAQ:BPTH$0.17 +0.00 (+1.47%) As of 10:33 AM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Clever Leaves NASDAQ:CLVR$0.0002 0.00 (0.00%) As of 04/2/2025Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.Kiora Pharmaceuticals NASDAQ:KPRX$2.76 -0.05 (-1.60%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Lipella Pharmaceuticals NASDAQ:LIPO$2.54 -0.04 (-1.55%) As of 10:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
